Exopharm is a world leader in the manufacture of exosome products.... more
Wednesday, February 12th, 2020 - Exopharm
An important step forward for Exopharm: A clinical-stage company and world leader in exosome therapeutics for regenerative medicine.... more
Monday, August 26th, 2019 - Exopharm
Melbourne, Australia: Exopharm Limited (ASX:EX1) has finalised a A$4.44 million share placement to new institutional and sophisticated investors. A further Share Purchase Plan (SPP) to existing shareholders has a target raise of A$2.7m.... more
Friday, July 26th, 2019 - Exopharm
Melbourne, Australia: Exopharm Limited (ASX:EX1) has received approval from Melbourne Health Human Research Ethics Committee to commence the PLEXOVAL wound healing study with its PlexarisTM product under the Australian Clinical Trials Notification (C... more
Monday, July 22nd, 2019 - Exopharm
Stem cell therapy once seemed beguilingly simple. It was thought that by injecting additional stem cells into the body, the new cells would transform the way that we treat certain conditions. But nearly 20 years on, the general safety and efficacy of... more
Thursday, July 18th, 2019 - Exopharm
Exopharm Limited is an Australian regenerative medicine biopharmaceutical company which is listed on the Australian Securities Exchange (ASX:EX1) seeking to develop and commercialise exosomes as therapeutic agents – initially a product called Plexaris™ and later a product called Exomeres™.
These products are exosomes that are derived from human platelets in relation to Plexaris, and adult stem cells in relation to Exomeres, and purified using the LEAP Technology and referred to as biologic products.
As its primary focus, Exopharm aims to be a leader in the field of human therapeutics using exosomes as regenerative medicine products for health span related conditions.P: +61 03 9111 0026
Scan the barcode to view this page on your Phone or Tablet.